Noramco, a provider of controlled substances, is adding commercial-scale capacity of dronabinol (THC) at its Athens, GA, facility. The expansion will support demand for the company’s highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.  Following implementation, Noramco will supply both THC and CBD from facilities in the U.S. and Europe. “Today’s announcement is further evidence that our pharmaceutical and healthcare customers place a significant value on our high...